Meta-analysis Reveals a Lack of Association Between UGT2B17 Deletion Polymorphism and Tumor Susceptibility.

Xiaheng Deng,Yidong Cheng,Xiao Yang,Shuang Li,Ruizhe Zhao,Kang Liu,Jinliang Liu,Qiang Cao,Chao Qin,Pengfei Shao,Xiaoxin Meng,Jie Li,Qiang Lu,Changjun Yin

DOI: https://doi.org/10.1371/journal.pone.0096812

IF: 3.7

2014-01-01

PLoS ONE

Abstract:Purpose UGT2B17 is a vital member of the UGT2 family and functions as a detoxification enzyme which catalyzes the glucuronidation of lipophilic compounds. Accumulating evidences implicates that it may contribute to the susceptibility of tumor risk. Identification of a UGT2B17 deletion polymorphism has attracted studies to evaluate the association between the UGT2B17 deletion polymorphism and tumor risk in diverse populations. However, the available results are conflicting. Methods A meta-analysis based on 14 studies from 10 publications including 5,732 cases and 5,112 controls was performed. Published literature from PubMed, EMBASE and Web of Science was pooled and the crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of the associations. Results Conclusively, our results indicate that individuals with a UGT2B17 deletion polymorphism were associated with tumor risks (OR = 1.29, 95% CI = 1.03–1.63, P<0.001) in a recessive model. However, after excluding two studies for their heterogeneity, the result then demonstrated that the UGT2B17 deletion polymorphism was not associated with tumor risks (OR = 1.118, 95%CI = 0.938–1.332, P>0.1). A subgroup analysis based on tumor type, sex or race did not show significant results. Conclusion These results suggest that the UGT2B17 deletion polymorphism is not associated with tumor risks.